Stock ALBIO BIOSYNEX
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biosynex

Equities

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris
Other stock markets
 11:35:25 2024-04-26 am EDT 		5-day change 1st Jan Change
4.09 EUR -0.73% Intraday chart for Biosynex -19.80% -51.02%
2023 Biosynex: merger with Theradiag completed CF
2023 Biosynex SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 30.42 22.84 23.75 151.6 289.9 141
Enterprise Value (EV) 1 34.83 26.04 31.26 130.6 193.2 105.9
P/E ratio 96.5 x 42.1 x 21.3 x 5.44 x 2.63 x 9.08 x
Yield - - - 1.2% 7.6% -
Capitalization / Revenue 0.99 x 0.73 x 0.69 x 0.99 x 0.76 x 0.72 x
EV / Revenue 1.14 x 0.83 x 0.9 x 0.85 x 0.5 x 0.54 x
EV / EBITDA 24.8 x 31 x 17.4 x 2.84 x 1.36 x 2.28 x
EV / FCF - - - 7,609,916 x 2,624,223 x -3,587,726 x
FCF Yield - - - 0% 0% -0%
Price to Book 1.05 x 0.78 x 0.78 x 2.29 x 1.62 x 0.87 x
Nbr of stocks (in thousands) 9,135 9,135 9,135 9,135 11,014 10,220
Reference price 2 3.330 2.500 2.600 16.60 26.32 13.80
Announcement Date 5/23/18 5/6/19 4/30/20 4/21/21 4/25/22 4/28/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 30.61 31.3 34.64 153.9 382.5 196.6
EBITDA 1 1.407 0.8389 1.797 46.02 141.8 46.49
EBIT 1 0.9219 0.3718 1.245 45.73 140.7 38.88
Operating Margin 3.01% 1.19% 3.59% 29.72% 36.77% 19.78%
Earnings before Tax (EBT) 1 0.1 0.3714 0.8999 43.52 136.9 24.18
Net income 1 0.3152 0.5429 1.116 31.37 104 15.66
Net margin 1.03% 1.73% 3.22% 20.38% 27.19% 7.96%
EPS 2 0.0345 0.0594 0.1221 3.050 10.01 1.520
Free Cash Flow - - - 17.16 73.61 -29.53
FCF margin - - - 11.15% 19.24% -15.02%
FCF Conversion (EBITDA) - - - 37.28% 51.91% -
FCF Conversion (Net income) - - - 54.7% 70.78% -
Dividend per Share - - - 0.2000 2.000 -
Announcement Date 5/23/18 5/6/19 4/30/20 4/21/21 4/25/22 4/28/23
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 4.41 3.2 7.51 - - -
Net Cash position 1 - - - 21.1 96.7 35.1
Leverage (Debt/EBITDA) 3.136 x 3.819 x 4.179 x - - -
Free Cash Flow - - - 17.2 73.6 -29.5
ROE (net income / shareholders' equity) 1.18% 1.87% 3.74% 64.8% 88.9% 9.33%
ROA (Net income/ Total Assets) 1.44% 0.58% 1.79% 33% 44.5% 9.18%
Assets 1 21.89 93.44 62.23 94.97 233.7 170.5
Book Value Per Share 2 3.160 3.200 3.330 7.240 16.30 15.90
Cash Flow per Share 2 0.2200 0.2000 0.2000 4.020 12.80 8.500
Capex - - - 9.12 19 30.1
Capex / Sales - - - 5.92% 4.97% 15.3%
Announcement Date 5/23/18 5/6/19 4/30/20 4/21/21 4/25/22 4/28/23
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
BIOSYNEX Stock Biosynex
-51.02% 46.99M
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.78% 5.41B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. ALBIO Stock
  4. Financials Biosynex